Sai Life Sciences Reports Robust Q2 Performance with Net Profit Doubling

Sai Life Sciences Limited , a leading Contract Research, Development and Manufacturing Services (CRDMO) provider, has announced its financial results for the second quarter, showcasing a remarkable improvement in both revenue and profitability.

Strong Financial Performance

The company reported a consolidated net profit of 838.44 million rupees for Q2, representing a significant increase from 415.10 million rupees in the same quarter last year. This translates to a year-on-year growth of approximately 102%, effectively doubling the company's bottom line.

Revenue from operations also saw substantial growth, rising to 5,374.70 million rupees compared to 3,955.62 million rupees in the corresponding quarter of the previous year, marking an increase of about 35.9%.

Key Financial Metrics

Here's a breakdown of the key financial metrics for Q2:

Metric	Current Q2 (in million rupees)	Previous Q2 (in million rupees)	YoY Change
Revenue from Operations	5,374.70	3,955.62	+35.9%
Net Profit	838.44	415.10	+102.0%
Total Income	5,527.95	4,055.15	+36.3%

Operational Highlights

The company's strong performance can be attributed to its focus on providing high-quality CRDMO services. The significant increase in revenue suggests growing demand for Sai Life Sciences' offerings in the pharmaceutical and biotechnology sectors.

Looking Ahead

As Sai Life Sciences continues to demonstrate strong financial performance, investors and industry observers may be watching closely to see if this growth trajectory can be maintained in the coming quarters. The company's ability to capitalize on opportunities in the evolving pharmaceutical research and manufacturing landscape will be crucial for its future success.

Sai Life Sciences' impressive Q2 results underscore its growing prominence in the CRDMO sector and may position the company favorably for future growth and expansion opportunities.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.09%	+0.21%	+6.47%	+27.90%	+20.62%	+20.62%

Sai Life Sciences , a prominent player in the pharmaceutical industry, has announced the allotment of 2,49,969 fully paid-up equity shares under its employee stock option plans. This move, approved by the company's Board of Directors through a circular resolution dated November 4, 2025, aims to attract, retain, and reward employees.

Details of the Allotment

The allotment includes shares issued under two distinct employee stock option plans:

Plan Name	Number of Shares	Exercise Price per Share
ESOP 2008	19,995	188.90
MESOP 2018	1,50,000	23.30
MESOP 2018	79,974	127.30

Impact on Share Capital

Following this allotment, Sai Life Sciences' total issued share capital has increased to 210,171,761 shares. The newly allotted shares have been issued in dematerialized form with the ISIN number INE570L01029.

Employee Stock Option Plans

The company's employee stock option plans, ESOP 2008 and MESOP 2018, are designed with a maximum vesting period of 5 years. These plans offer flexibility with multiple vesting options, allowing employees to exercise their options as long as they remain in the company's service.

Financial Implications

The total money realized by the company through this exercise of options amounts to INR 1,74,52,745.70. This infusion of capital could potentially contribute to the company's growth initiatives and operational needs.

Regulatory Compliance

Sai Life Sciences has ensured compliance with the Securities and Exchange Board of India (SEBI) regulations, including the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

This allotment of shares under the employee stock option plans underscores Sai Life Sciences' commitment to aligning employee interests with the company's long-term growth objectives.